{"id":"W4390743174","doi":"10.1007/s40120-023-00565-7","title":"Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Greenwich Biosciences; EMD Serono; Genentech; Horizon Therapeutics; Mylan; TG Therapeutics; Biogen; Celgene; Sanofi Genzyme; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Jazz Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Sanofi; MedDay Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Multiple sclerosis; Neurology; Clinical trial; Immunosuppression; Disease; Interferon beta; Interferon beta-1a; Glatiramer acetate; Internal medicine; Oncology; Pediatrics; Immunology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004124397,0.0005983565,0.0007711026,0.0006970263,0.0002965737,0.001529344,0.0005913816,0.001598197,0.002986753],"category_scores_gemma":[0.003667637,0.0001586383,0.0004453182,0.0008839993,0.001234565,0.002147808,0.0006029874,0.003101681,0.001365329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009220123,"about_ca_system_score_gemma":0.001345428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005137059,"about_ca_topic_score_gemma":0.001029685,"domain_scores_codex":[0.9992771,0.0002659498,0.0001176266,0.0001040125,0.0001771104,0.00005830938],"domain_scores_gemma":[0.9976462,0.001254095,0.0003181999,0.00008810334,0.0004182128,0.0002751703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008120592,0.0002224716,0.0007429075,0.0031855,0.00009103803,0.0002929571,0.0001941295,0.0002143201,0.001474241,0.01318697,0.04344846,0.9361349],"study_design_scores_gemma":[0.0003143191,0.001556102,0.002149044,0.004800796,0.0001901755,0.001490294,0.0001666432,0.0002057574,0.0004726384,0.007558602,0.981066,0.00002965034],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009394288,0.9825916,0.0003065541,0.01250713,0.001589857,0.000006089867,0.00001903798,0.00001052191,0.002029697],"genre_scores_gemma":[0.01322792,0.9599036,0.0007946207,0.01522958,0.009186542,0.00004358396,0.00007555825,0.0000136328,0.001524901],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004124397,"threshold_uncertainty_score":0.0218122,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09876984893684974,"score_gpt":0.322607626696812,"score_spread":0.2238377777599623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}